Thanks, appreciated Kurt. I agree, the platform has already proven itself by generating many useful compounds which are now being commercialized by five different subsidiaries, some of which already selling commercial products and some of them worth more than Evogene itself.

Yes, thanks, this would help many people. 

Thanks people, it seems a pretty good opportunity here, IMHO.

Thanks Derek, appreciated.

Thanks, appreciated!

So they have a $96M market cap, rather than the $130M I assumed in the article and an EV of $76M, that's quite a bit less..

You're right, bit of a confusing sentence (the one quoted from the 10Q) but I read that the wrong way. First time I've seen that split out into 3 and 9 month periods, but they are almost entirely overlapping, not separate quantities I now realize.

Well, signs of:

• Happy customers expanding deployments
• Trials converting into deployments

It's now a $35M company, fully diluted with perhaps $20M in cash already after a lot of warrants converted recently. Just a little traction needed to turn this around, IMHO

Thanks people, solid Q3 results